# Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial

> **NCT07167160** · PHASE2 · RECRUITING · sponsor: **Women's Hospital School Of Medicine Zhejiang University** · enrollment: 59 (estimated)

## Conditions studied

- Cervical Cancer
- Immunochemotherapy

## Interventions

- **DRUG:** Camrelizumab combined with chemotherapy

## Key facts

- **NCT ID:** NCT07167160
- **Lead sponsor:** Women's Hospital School Of Medicine Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-10
- **Primary completion:** 2026-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07167160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07167160, "Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07167160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*